US Stock MarketDetailed Quotes

STRO Sutro Biopharma

Watchlist
  • 1.870
  • -0.010-0.53%
Close Dec 23 16:00 ET
  • 1.870
  • 0.0000.00%
Post 16:01 ET
154.20MMarket Cap-1.21P/E (TTM)
Post-Market
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Dec 10 07:09
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
    Tuesday, 10th December at 8:00 am
    - 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
    - These data confirm luvelta's robust response rate in patients with late-stage ovarian c...
    Trytosaveabit
    Trytosaveabit
    Nov 1 07:03
    Update
    $Sutro Biopharma (STRO.US)$ Reuters· 2 mins ago
    Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml
    Jaguar8
    Jaguar8
    Nov 1 07:02
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
    Sutro Biopharma has initiated REFRαME-P1, a registration-enabling trial of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML. The study follows encouraging compassionate use data presented in December 2023, showing 42% complete remission in patients with ≥5% blasts. CBF/GLIS AML is a rare, aggressive leuke...
    Jaguar8
    Jaguar8
    Oct 10 15:06
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
    Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory...
    Jaguar8
    Jaguar8
    Sep 14 02:03
    WEEKEND NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
    Sutro Biopharma (NASDAQ: STRO) announced updated data from its Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for epithelial ovarian cancer (EOC) at ESMO 2024. Key findings include:
    - 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
    - 35% overal...
Read more
Trending US Stocks
Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Symbol Mini Chart % Chg
New Fortress Energy
NFE
+21.74%
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
+8.49%
Dorian LPG
LPG
+4.83%
Precision Drilling
PDS
+2.46%
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
+1.94%

Unlock the Full List